ArriVent Announces Positive Phase 1b Data For Firmonertinib In NSCLC With EGFR PACC Mutations
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – ArriVent BioPharma Inc. (AVBP) announced positive proof-of-concept randomized global Phase 1b FURTHER interim data for first-line firmonertinib monotherapy in patients with non-small cell lung cancer or NSCLC harboring EGFR PACC mutations.
:max_bytes(150000):strip_icc():format(jpeg)/socialsecurity-whentoapply-794e7d2e1615450a9c7530288e2f5dad.jpg "Unlocking Benefits: The Best Time to Apply for Social Security")
:max_bytes(150000):strip_icc():format(jpeg)/creditscorecheck-c254d4f39aae46919b846f0f391011c6.jpg "Watch Out for These Top Internet Scams")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-685011611-3857c64421274483b5cc2ee96db5b57e.jpg "How to Choose a Credit Repair Company")
:max_bytes(150000):strip_icc():format(jpeg)/globaltrade-8e91fb7b1b8047988ef6b7acb0280bf5.png "International (Global) Trade: Definition, Benefits, and Criticisms")
:max_bytes(150000):strip_icc():format(jpeg)/Mediation-56a260535f9b58b7d0c975bb.jpg "How Divorce Impacts Your Credit Score")